# ë°°ê²½ ìë£Œ: MSK Award Lecture - ë§Œì„± ì§ˆí™˜ ì¹˜ë£Œë¥¼ ìœ„í•œ ë§ˆì´í¬ë¡œë°”ì´ì˜´ ê³¼í•™ì˜ ìƒˆë¡œìš´ ì‹œëŒ€

**ë°œí‘œ**: AL - MSK Award Lecture (2024 Academic Research Awardee)
**ì¼ì‹œ**: 2025ë…„ 10ì›” 28ì¼ (í™”) 13:00-13:40
**ì¥ì†Œ**: Convention Hall 1
**ì¢Œì¥**: Jang-Cheon Cho (Inha University)
**ì¤‘ìš”ë„**: â­â­â­â­â­ (96/100ì ) - **Award Lecture! ë§ˆì´í¬ë¡œë°”ì´ì˜´ ì—°êµ¬ì í•„ìˆ˜**

---

## ğŸ¯ ë°œí‘œ ê°œìš”

**ì—°ì‚¬**: ê³ ê´‘í‘œ (GwangPyo Ko)
**ì†Œì†**: Seoul National University (ì„œìš¸ëŒ€í•™êµ)
**ì§ì±…**:
- Professor, School of Public Health, Dept. of Environmental Health Sciences
- Director, Center for Human and Environmental Microbiome
- Founder, KoBioLabs, Inc.

**ì œëª©**: Emerging era of microbiome science for chronic diseases therapeutics

### ì™œ ì´ ë°œí‘œê°€ ì¤‘ìš”í•œê°€?

- ğŸ† **MSK 2024 Academic Research Award ìˆ˜ìƒì**: í•œêµ­ ë¯¸ìƒë¬¼í•™ê³„ ìµœê³  ì˜ì˜ˆ
- ğŸ‡°ğŸ‡· **í•œêµ­ ë§ˆì´í¬ë¡œë°”ì´ì˜´ ì—°êµ¬ì˜ ì„ êµ¬ì**: êµ­ë‚´ microbiome therapeutics ì‚°ì—… ì£¼ë„
- ğŸ”¬ **ë§Œì„± ì§ˆí™˜ ì¹˜ë£Œ**: IBD, NAFLD, T2DM ë“±ì— ëŒ€í•œ microbiome ê¸°ë°˜ ì¹˜ë£Œë²•
- ğŸ’Š **Translational research**: ê¸°ì´ˆ ì—°êµ¬ â†’ ì„ìƒ â†’ ìƒì—…í™” (KoBioLabs ì°½ì—…)
- ğŸ“Š **2024 KDDW ë°œí‘œ**: IBD microbial therapeutics ê°œë°œì˜ ê³¼ì œì™€ í•´ê²°ì±…

### ë© êµ¬ì„±ì›ë“¤ì—ê²Œ ìœ ìš©í•œ ì´ìœ 

**ë§ˆì´í¬ë¡œë°”ì´ì˜´ ì—°êµ¬ì**:
- í•œêµ­ì¸ ì½”í˜¸íŠ¸ ê¸°ë°˜ microbiome ì—°êµ¬ ì‚¬ë¡€
- Gut microbiome signatures in metabolic diseases
- ì‹¤ì „ì  microbiome ë¶„ì„ ë°©ë²•ë¡ 

**ì„ìƒ/ì¤‘ê°œ ì—°êµ¬ì**:
- Microbiome-based therapeutics ê°œë°œ ê³¼ì •
- ì„ìƒ ì‹œí—˜ ì„¤ê³„ ë° hurdles
- ê·œì œ ë° ìƒì—…í™” ì „ëµ

**ë°”ì´ì˜¤ë²¤ì²˜ ê´€ì‹¬ì**:
- KoBioLabs ì°½ì—… ìŠ¤í† ë¦¬
- Microbiome ì‚°ì—…ì˜ í˜„ì¬ì™€ ë¯¸ë˜
- í•œêµ­ microbiome ì‹œì¥ ë™í–¥

**ê³µì¤‘ë³´ê±´ ì—°êµ¬ì**:
- Environmental healthì™€ microbiome
- Host-microbiome interaction in disease
- Public health interventionìœ¼ë¡œì„œì˜ microbiome

---

## ğŸ“‹ ì—°ì‚¬ ë°°ê²½ ë° ì£¼ìš” ì—°êµ¬

### ê³ ê´‘í‘œ êµìˆ˜ ì†Œê°œ

**í•™ë ¥ ë° ê²½ë ¥**:
- **í˜„ì¬**: ì„œìš¸ëŒ€í•™êµ ë³´ê±´ëŒ€í•™ì› í™˜ê²½ë³´ê±´í•™ê³¼ êµìˆ˜
- **Center for Human and Environmental Microbiome** ì„¼í„°ì¥
- **KoBioLabs, Inc.** ì°½ì—…ì (Microbiome therapeutics íšŒì‚¬)

**ì—°êµ¬ ë¶„ì•¼**:
- Human gut microbiome and chronic diseases
- Environmental microbiome (water, food)
- Microbiome-based diagnostics and therapeutics
- One Health approach

**ì£¼ìš” Achievement**:
- **2024**: MSK Academic Research Award ìˆ˜ìƒ
- Synthetic gut microbiome ì—°êµ¬ (PMC, 2020)
- Akkermansia muciniphila ì¹˜ë£Œì  í™œìš© (PMC, 2022)
- Korean microbiome ì‚°ì—… ì£¼ë„

### ì£¼ìš” ì—°êµ¬ ì„±ê³¼

#### 1. Type 2 Diabetesì™€ Gut Microbiome (PMC, 2021)

**ë…¼ë¬¸**: "Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease"

**í•µì‹¬ ë°œê²¬**:
- Korean cohortì—ì„œ T2DMê³¼ NAFLDì˜ gut microbiome signature êµ¬ë³„
- Disease-specific microbial markers ë°œêµ´
- Diagnostic potential

**ì˜ë¯¸**:
- Microbiome-based precision medicine ê°€ëŠ¥ì„±
- í•œêµ­ì¸ íŠ¹ì´ì  microbiome pattern ì¡´ì¬

#### 2. NAFLD Microbiome Signatures (PMC, 2020)

**ë…¼ë¬¸**: "Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD"

**íŠ¹ì§•**:
- Non-obese NAFLD í™˜ìì˜ ë…íŠ¹í•œ microbiome
- Gut microbiome + metabolites í†µí•© ë¶„ì„
- Fibrosis progressionê³¼ ì—°ê´€ëœ microbial taxa

#### 3. Akkermansia muciniphilaì˜ ì¹˜ë£Œì  ê°€ëŠ¥ì„± (PMC, 2022)

**ë¦¬ë·°**: "Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium"

**ë‚´ìš©**:
```
A. muciniphilaì˜ ìœ ìµí•œ íš¨ê³¼:
  â†’ Metabolic health (obesity, T2DM ê°œì„ )
  â†’ Gut barrier integrity (mucus layer ê°•í™”)
  â†’ Anti-inflammatory effects
  â†’ Immunotherapy response ì¦ì§„ (ì•” ì¹˜ë£Œ)

ì¹˜ë£Œì œ ê°œë°œ ì „ëµ:
  â†’ Live bacteria administration
  â†’ Pasteurized form (ë” ì•ˆì •ì )
  â†’ Outer membrane protein Amuc_1100 (active component)
  â†’ Prebiotic approach (inulin ë“±ìœ¼ë¡œ A. muciniphila ì¦ê°€)
```

#### 4. Synthetic Gut Microbiome (PMC, 2020)

**ë¦¬ë·°**: "Synthetic gut microbiome: Advances and challenges"

**ì£¼ì œ**:
```
Defined microbial consortium:
  â†’ Reproducibility (batch-to-batch variation ì—†ìŒ)
  â†’ Safety (pathogen-free)
  â†’ Mechanistic studies ê°€ëŠ¥

Applications:
  â†’ FMT alternative (Fecal Microbiota Transplantation ëŒ€ì²´)
  â†’ Personalized microbiome therapy
  â†’ Microbiome engineering
```

#### 5. IBD Microbial Therapeutics (KDDW 2024)

**ë°œí‘œ**: "Development of microbial therapeutics in IBD: hurdles and potential solutions"

**ì£¼ìš” ë‚´ìš©** (ì˜ˆìƒ):
```
Hurdles:
  1. Engraftment failure (ì •ì°© ì‹¤íŒ¨)
  2. Inter-individual variability (ê°œì¸ì°¨)
  3. Host immune response
  4. Regulatory challenges (í—ˆê°€)
  5. Manufacturing (GMP ìƒì‚°)

Solutions:
  1. Pre-conditioning (í•­ìƒì œ, prebiotics)
  2. Strain selection (colonization capacity)
  3. Formulation optimization (survival, delivery)
  4. Companion diagnostics (responder ì˜ˆì¸¡)
  5. Clinical trial design (endpoints, biomarkers)
```

---

## ğŸ”¬ ë°œí‘œ ì˜ˆìƒ ë‚´ìš©

### Part 1: Microbiome and Chronic Diseases

#### 1-1. Gut Microbiomeì˜ ì§ˆë³‘ ì—°ê´€ì„±

**ì£¼ìš” ë§Œì„± ì§ˆí™˜**:

```yaml
Metabolic Diseases:
  - Type 2 Diabetes (T2DM)
  - Non-Alcoholic Fatty Liver Disease (NAFLD)
  - Obesity
  - Metabolic syndrome

Inflammatory Diseases:
  - Inflammatory Bowel Disease (IBD)
    â”œâ”€ Crohn's disease
    â””â”€ Ulcerative colitis
  - Allergies

Neurological:
  - Parkinson's disease
  - Autism spectrum disorder

Cancer:
  - Colorectal cancer
  - Liver cancer
```

**ê³µí†µ ë©”ì»¤ë‹ˆì¦˜**:
```
Dysbiosis (microbiome imbalance)
    â†“
    â”œâ†’ Metabolic dysfunction (SCFA ê°ì†Œ, LPS ì¦ê°€)
    â”œâ†’ Immune dysregulation (Th17/Treg imbalance)
    â”œâ†’ Barrier disruption (Leaky gut)
    â””â†’ Systemic inflammation
    â†“
Chronic disease progression
```

#### 1-2. í•œêµ­ì¸ Microbiome íŠ¹ì„±

**ê³ ê´‘í‘œ êµìˆ˜ íŒ€ì˜ ë°œê²¬**:

**T2DM vs. NAFLD microbiome**:
```
T2DM-enriched:
  - Certain Bacteroides species
  - Altered SCFA producers

NAFLD-enriched:
  - Fibrosis-associated taxa
  - Metabolite profiles (bile acids, choline metabolism)

Overlap but distinguishable:
  â†’ Disease-specific signatures ì¡´ì¬
  â†’ Diagnostic biomarkers ê°€ëŠ¥
```

**Korean population íŠ¹ì´ì„±**:
- ì‹ì´ (kimchi, fermented foods) ì˜í–¥
- Genetic background (East Asian)
- Environmental factors

### Part 2: Microbiome-based Therapeutics

#### 2-1. í˜„ì¬ ì ‘ê·¼ë²•ë“¤

**Category 1: Live Biotherapeutics (LBPs)**

```
Single strain:
  ì˜ˆ: E. coli Nissle 1917, Akkermansia muciniphila
  ì¥ì : ëª…í™•í•œ mechanism, í’ˆì§ˆ ê´€ë¦¬ ìš©ì´
  ë‹¨ì : Engraftment ì–´ë ¤ì›€, ì œí•œì  íš¨ê³¼

Defined consortia:
  ì˜ˆ: VE303 (8-strain), SER-287 (Firmicutes spores)
  ì¥ì : Synergy, ì•ˆì •ì„±
  ë‹¨ì : ë³µì¡ë„, regulatory hurdles

Fecal Microbiota Transplantation (FMT):
  ì¥ì : ê°•ë ¥í•œ íš¨ê³¼ (C. diffì—ì„œ 90% ì„±ê³µë¥ )
  ë‹¨ì : Standardization ì–´ë ¤ì›€, safety ìš°ë ¤
```

**Category 2: Prebiotics**
```
ì •ì˜: Microbiomeì„ ì„ íƒì ìœ¼ë¡œ modulationí•˜ëŠ” ì‹ì´ ì„±ë¶„
ì˜ˆ: Inulin, FOS, GOS
íš¨ê³¼: ìœ ìµê·  (Bifidobacterium, Akkermansia) ì¦ê°€
ì¥ì : ì•ˆì „, ì €ë ´
ë‹¨ì : íš¨ê³¼ ì•½í•¨, ê°œì¸ì°¨
```

**Category 3: Postbiotics**
```
ì •ì˜: ë¯¸ìƒë¬¼ ëŒ€ì‚¬ì‚°ë¬¼ ë˜ëŠ” dead cell components
ì˜ˆ: SCFAs (butyrate), Outer membrane proteins
ì¥ì : ì•ˆì •ì , ëª…í™•í•œ mechanism
ë‹¨ì : ë‹¨ì¼ ì„±ë¶„, ë³µì¡í•œ microbiome íš¨ê³¼ ì¬í˜„ ì–´ë ¤ì›€
```

**Category 4: Engineered Bacteria**
```
Synthetic biology approach:
  â†’ Bacteriaë¥¼ "drug delivery vehicle"ë¡œ ì‚¬ìš©
  â†’ Anti-inflammatory cytokines ìƒì‚°
  â†’ Tumor-targeting bacteria (cancer therapy)

ì˜ˆ: Genetically modified E. coli Nissle producing IL-10
```

#### 2-2. Akkermansia muciniphila - Case Study

**ì™œ A. muciniphila?**

**íŠ¹ì„±**:
```
- Mucin-degrading bacterium (mucus layer ê±°ì£¼)
- Healthy individualsì— í’ë¶€
- Obesity, T2DM í™˜ìì—ì„œ ê°ì†Œ
- Next-generation probiotic í›„ë³´
```

**ì„ìƒ ì—°êµ¬**:
```
Human trial (2019, Nature Medicine):
  - Overweight/obese adults
  - Pasteurized A. muciniphila íˆ¬ì—¬ (10^10 CFU/day, 3 months)
  - ê²°ê³¼:
    â”œâ†’ Insulin sensitivity ê°œì„ 
    â”œâ†’ Cholesterol ê°ì†Œ
    â””â†’ Inflammatory markers ê°ì†Œ

Active component:
  - Amuc_1100 (outer membrane protein)
  - TLR2 activator â†’ Immune modulation
```

**KoBioLabsì˜ ê°œë°œ ì „ëµ** (ì¶”ì •):
```
Product forms:
  1. Live A. muciniphila (refrigerated)
  2. Pasteurized form (stable, room temperature)
  3. Amuc_1100 protein (precision medicine)

Target indications:
  - Metabolic syndrome
  - NAFLD/NASH
  - IBD (adjunct therapy)
```

#### 2-3. IBD Therapeutics - Hurdles and Solutions

**Challenge 1: Engraftment Failure**
```
ë¬¸ì œ: ëŒ€ë¶€ë¶„ì˜ probiotic bacteriaëŠ” ì¥ì— ì •ì°© ëª» í•¨
        (Transient colonizationë§Œ)

Solutions:
  - Pre-conditioning: í•­ìƒì œë¡œ niche í™•ë³´
  - Strain selection: ë†’ì€ colonization capacity
  - Co-administration: Prebiotics, mucus-binding enhancers
  - Formulation: Enteric coating, bile acid resistance
```

**Challenge 2: Inter-individual Variability**
```
ë¬¸ì œ: ê°™ì€ ì¹˜ë£Œì— ë°˜ì‘í•˜ëŠ” ì‚¬ëŒ vs. ì•ˆ í•˜ëŠ” ì‚¬ëŒ

Solutions:
  - Baseline microbiome profiling (responder ì˜ˆì¸¡)
  - Personalized therapy (individual microbiome ê¸°ë°˜)
  - Combination therapy (multiple strains or + drugs)
```

**Challenge 3: Regulatory Path**
```
ë¬¸ì œ: LBPëŠ” drugì¸ê°€ biologicì¸ê°€? ê·œì œ ë¶ˆëª…í™•

í•œêµ­/ë¯¸êµ­/EU ë™í–¥:
  - FDA: Live Biotherapeutic Products (LBP) ê°€ì´ë“œë¼ì¸ (2016)
  - EMA: Similar framework
  - MFDS (í•œêµ­): ê°œë°œ ì¤‘, ì•„ì§ ëª…í™•í•œ pathway ë¶€ì¡±

KoBioLabs approach:
  - ì„ìƒ ë°ì´í„° ì¶•ì 
  - GMP ì œì¡° ì‹œì„¤ êµ¬ì¶•
  - ê¸€ë¡œë²Œ regulatory ì „ë¬¸ê°€ í˜‘ë ¥
```

**Challenge 4: Manufacturing**
```
ë¬¸ì œ: Anaerobic bacteria ëŒ€ëŸ‰ ìƒì‚°, ì•ˆì •ì„± í™•ë³´

Solutions:
  - Spore-forming bacteria ì„ í˜¸ (Bacillus, Clostridium)
  - Lyophilization (freeze-drying)
  - Microencapsulation
  - Cold chain management
```

### Part 3: í•œêµ­ Microbiome ì‚°ì—…ì˜ í˜„ì¬ì™€ ë¯¸ë˜

#### 3-1. í•œêµ­ Microbiome ê¸°ì—…ë“¤ (2024 ê¸°ì¤€)

**ì£¼ìš” ê¸°ì—…**:
```
1. KoBioLabs (Ko êµìˆ˜ ì°½ì—…)
   - Akkermansia-based therapeutics
   - Metabolic diseases íƒ€ê²Ÿ

2. MDimune
   - Cancer immunotherapy + microbiome

3. Genome & Company
   - Precision microbiome analysis

4. Bifido (CJ ê³„ì—´)
   - Bifidobacterium-based probiotics

5. Enterobiome
   - IBD therapeutics

6. HEM Pharma
   - FMT standardization

7. Macrogen
   - Microbiome diagnostics
```

**íˆ¬ì ë™í–¥**:
- 2024ë…„ê¹Œì§€ ì´ íˆ¬ìì•¡: ìˆ˜ë°±ì–µ ì›
- Microbiome Asia Conference (2024) ê°œìµœ
- ì •ë¶€ ì§€ì› ì¦ê°€ (ë³´ê±´ì‚°ì—…ì§„í¥ì› ë“±)

#### 3-2. Global Microbiome Market

**ì‹œì¥ ê·œëª¨**:
```
2023: $1.5 billion
2030 (ì˜ˆì¸¡): $10+ billion
CAGR: ~20%
```

**ì„ ë„ ê¸°ì—…**:
```
- Seres Therapeutics (SER-109: C. diff)
- Vedanta Biosciences (VE303: GVHD)
- Finch Therapeutics (FMT-based)
- Second Genome â†’ Gilead ì¸ìˆ˜
```

#### 3-3. ë¯¸ë˜ ë°©í–¥

**Precision Microbiome Medicine**:
```
Workflow:
  1. Baseline microbiome sequencing
  2. AI/ML-based responder prediction
  3. Personalized therapy selection
  4. Monitoring & adjustment
```

**Microbiome + Other Therapies**:
```
Combination:
  - Microbiome + Immunotherapy (cancer)
  - Microbiome + Diet intervention
  - Microbiome + Pharmacotherapy (synergy or reduce side effects)
```

**Preventive Medicine**:
```
- Early-life microbiome intervention (neonatal)
- Microbiome-targeted functional foods
- Public health campaigns (fermented foods, fiber)
```

---

## ğŸ’¡ ì˜ˆìƒ ì§ˆë¬¸ ë° í† ë¡  í¬ì¸íŠ¸

### ë°œí‘œ ì¤‘/í›„ ë¬¼ì–´ë³¼ ì§ˆë¬¸ë“¤

**1. KoBioLabs ìƒì—…í™” ì „ëµ**:
> "KoBioLabsì˜ lead productëŠ” ë¬´ì—‡ì´ê³ , í˜„ì¬ ì„ìƒ ë‹¨ê³„ëŠ” ì–´ë””ì¸ê°€ìš”?"

**ë°°ê²½**: ì°½ì—…ìë¡œì„œì˜ ê²½í—˜ ê³µìœ 

**2. í•œêµ­ì¸ íŠ¹ì´ì„±**:
> "í•œêµ­ì¸ microbiomeì˜ ë…íŠ¹í•œ ì ì´ ì¹˜ë£Œì œ ê°œë°œì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ë‚˜ìš”?"

**ë°°ê²½**: Population-specific medicine

**3. IBD ì¹˜ë£Œ ì „ë§**:
> "í˜„ì¬ IBD ì¹˜ë£Œì œ (anti-TNF ë“±)ì™€ ë¹„êµí–ˆì„ ë•Œ microbiome ì¹˜ë£Œì˜ ìœ„ì¹˜ëŠ”?"

**ë°°ê²½**: ê¸°ì¡´ ì¹˜ë£Œì™€ì˜ í†µí•©

**4. ì‚°í•™í˜‘ë ¥**:
> "ëŒ€í•™ ì—°êµ¬ì™€ íšŒì‚¬ ìš´ì˜ì„ ì–´ë–»ê²Œ balanceí•˜ì‹œë‚˜ìš”? Conflict of interestëŠ”?"

**ë°°ê²½**: ì‹¤ë¬´ì  ì¡°ì–¸

**5. ì •ë¶€ ì •ì±… ì œì–¸**:
> "í•œêµ­ì´ microbiome ì‚°ì—…ì„ í‚¤ìš°ë ¤ë©´ ì •ë¶€ê°€ ë¬´ì—‡ì„ í•´ì•¼ í• ê¹Œìš”?"

**ë°°ê²½**: ê³µì¤‘ë³´ê±´ ì •ì±…

---

## ğŸ“š ì¶”ì²œ ì‚¬ì „ í•™ìŠµ ìë£Œ

### í•„ìˆ˜ ë…¼ë¬¸ (ê³ ê´‘í‘œ êµìˆ˜ íŒ€)

**1. Metabolic diseases**:
```
1) "Gut microbiome signatures distinguish T2DM from NAFLD" (PMC, 2021)
2) "Distinct signatures in non-obese NAFLD" (PMC, 2020)
```

**2. Therapeutics**:
```
3) "Revisiting Akkermansia muciniphila as therapeutic bacterium" (PMC, 2022)
4) "Synthetic gut microbiome: Advances and challenges" (PMC, 2020)
```

**3. Aging & longevity** (if covered):
```
5) "Microbiome-based therapeutics towards healthier aging" (PMC, 2024)
```

### í•µì‹¬ ê°œë… ë³µìŠµ

**ë°˜ë“œì‹œ ì•Œì•„ì•¼ í•  ìš©ì–´**:
- **Dysbiosis**: Microbiome imbalance
- **LBP** (Live Biotherapeutic Product): ì‚´ì•„ìˆëŠ” ë¯¸ìƒë¬¼ ì¹˜ë£Œì œ
- **FMT** (Fecal Microbiota Transplantation): ë¶„ë³€ ë¯¸ìƒë¬¼ ì´ì‹
- **Akkermansia muciniphila**: Next-generation probiotic
- **Engraftment**: ì¥ë‚´ ì •ì°©
- **SCFA** (Short-Chain Fatty Acids): ë¯¸ìƒë¬¼ ëŒ€ì‚¬ì‚°ë¬¼ (butyrate, acetate, propionate)

---

## ğŸŒŸ ì´ ë°œí‘œì˜ í•˜ì´ë¼ì´íŠ¸

### Take-home Messages

**1. Microbiome = ì§ˆë³‘ ì¹˜ë£Œì˜ ìƒˆ ì§€í‰**:
- ë§Œì„± ì§ˆí™˜ì˜ microbiome ê¸°ë°˜ ì¹˜ë£Œ ê°€ëŠ¥ì„±
- Precision medicineì˜ í•µì‹¬ ìš”ì†Œ

**2. ê¸°ì´ˆ ì—°êµ¬ â†’ ì„ìƒ â†’ ì‚°ì—…í™”**:
- í•œêµ­ ì—°êµ¬ìì˜ translational research ì„±ê³µ ì‚¬ë¡€
- KoBioLabs ì°½ì—… ìŠ¤í† ë¦¬

**3. Hurdles and Solutions**:
- IBD ì¹˜ë£Œì œ ê°œë°œì˜ í˜„ì‹¤ì  ì–´ë ¤ì›€
- ê·¹ë³µ ì „ëµ ì œì‹œ

**4. í•œêµ­ Microbiome ì‚°ì—…ì˜ ë¯¸ë˜**:
- ê¸€ë¡œë²Œ ê²½ìŸë ¥
- ì •ì±…ì  ì§€ì› í•„ìš”ì„±

### ë„¤íŠ¸ì›Œí‚¹ í¬ì¸íŠ¸

**ê³ ê´‘í‘œ êµìˆ˜ì™€ ëŒ€í™” ì‹œ ì–¸ê¸‰í•˜ë©´ ì¢‹ì„ ì£¼ì œ**:
- "MSK Award ìˆ˜ìƒ ì§„ì‹¬ìœ¼ë¡œ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤!"
- "KoBioLabsì˜ Akkermansia ì œí’ˆì´ ê¸°ëŒ€ë©ë‹ˆë‹¤"
- "í•œêµ­ì¸ ì½”í˜¸íŠ¸ ì—°êµ¬ê°€ ë§¤ìš° ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤"
- "KDDW 2024 ë°œí‘œ ì¸ìƒ ê¹Šê²Œ ë“¤ì—ˆìŠµë‹ˆë‹¤" (ë§Œì•½ ë“¤ì—ˆë‹¤ë©´)
- "Microbiome ì—°êµ¬ë¥¼ ì‹œì‘í•˜ë ¤ëŠ” í•™ìƒì—ê²Œ ì¡°ì–¸ ë¶€íƒë“œë¦½ë‹ˆë‹¤"

**í˜‘ì—… ê°€ëŠ¥ì„±**:
- í•œêµ­ì¸ microbiome ë°ì´í„° í˜‘ë ¥
- Clinical samples ì œê³µ
- Postdoc/graduate student exchange

**ê´€ë ¨ ì„¸ì…˜ ì—°ê³„**:
- **S2 (Diet-Microbiome-Host)**
- **S9, S11, S15 (Microbiome sessions)**
- **S20 (One Health)**: Environmental microbiome

---

## ğŸ“Š ë°œí‘œ í‰ê°€ ê¸°ì¤€

### ìš°ì„ ìˆœìœ„: â­â­â­â­â­ (96/100)

**ì°¸ì„ ì´ìœ **:
```
âœ… MSK Award Lecture (ìµœê³  ì˜ì˜ˆ!)
âœ… í•œêµ­ microbiome ì—°êµ¬ ì„ êµ¬ì
âœ… Translational research ëª¨ë²” ì‚¬ë¡€
âœ… ì‚°ì—…í™” ì„±ê³µ ìŠ¤í† ë¦¬ (KoBioLabs)
âœ… ì‹¤ë¬´ì  insights (hurdles & solutions)
âœ… í•œêµ­ì¸ì—ê²Œ íŠ¹íˆ ì˜ë¯¸ ìˆìŒ
```

**ëˆ„ê°€ ë“¤ì–´ì•¼ í•˜ë‚˜**:
- âœ… **Microbiome ì—°êµ¬ì** (í•„ìˆ˜!)
- âœ… **ì„ìƒ/ì¤‘ê°œ ì—°êµ¬ì**
- âœ… **ë°”ì´ì˜¤ë²¤ì²˜ ê´€ì‹¬ì**
- âœ… **í•™ìƒ/postdoc** (career guidance)
- âœ… **ê³µì¤‘ë³´ê±´ ì—°êµ¬ì**
- âš ï¸ ëª¨ë“  ì°¸ê°€ì ê°•ë ¥ ì¶”ì²œ (í•œêµ­ ì—°êµ¬ ë¡¤ëª¨ë¸)

**ì˜ˆìƒ ë¶„ìœ„ê¸°**:
- ìë‘ìŠ¤ëŸ¬ìš´ ìˆœê°„ (í•œêµ­ ì—°êµ¬ìì˜ ì„±ê³¼)
- ì‹¤ìš©ì  ì •ë³´ (ì°½ì—…, ì‚°ì—…í™”)
- ë„¤íŠ¸ì›Œí‚¹ ê¸°íšŒ (êµ­ë‚´ í˜‘ë ¥)

---

**ì‘ì„±ì¼**: 2025-10-26
**ì‘ì„±ì**: Conference Advisor (MSK2025 ì¤€ë¹„íŒ€)
**ì°¸ê³  ë¬¸í—Œ**: PMC 2020-2024 publications, KDDW 2024, Microbiome Asia 2024
